Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ublituximab - TG Therapeutics

Drug Profile

Ublituximab - TG Therapeutics

Alternative Names: EMAB-6; LFB-R603; R603; Rituximab biobetter - TG Therapeutics; TG-1101; TGTX-1101; Utuxin

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LFB Biotechnologies; rEVO Biologics
  • Developer Johns Hopkins University; LFB Biotechnologies; TG Therapeutics Inc
  • Class Antineoplastics; Biobetters; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica; Chronic lymphocytic leukaemia; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia; Multiple sclerosis
  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Neuromyelitis optica

Most Recent Events

  • 03 Dec 2019 Updated efficacy, adverse events and pharmacokinetics data from a phase I trial in Non-Hodgkin's lymphoma and Chronic lymphocytic leukaemia presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
  • 07 Nov 2019 Adverse events and efficacy data from a phase I trial in Non-Hodgkin's lymphoma and Chronic lymphocytic leukaemia released by TG Therapeutics
  • 07 Nov 2019 Efficacy and adverse events data from a phase I/II trial in Chronic lymphocytic leukaemia released by TG Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top